Navidea Biopharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Navidea Biopharmaceuticals generated cash of -$8,986,570, which is more than the previous year. Cash used in financing activities reached the amount of $7,141,914 last year. Net change in cash is therefore -$2,235,005.
Cash Flow
| 2013 | -35.61M | -1.29M | 60.72M |
|---|---|---|---|
| 2014 | -29.12M | -1.52M | 3.19M |
| 2015 | -19.07M | -27.82K | 20.79M |
| 2016 | 3.55M | -39.22K | -9.14M |
| 2017 | 59.08M | -1.83M | -55.99M |
| 2018 | 4.27M | 953.80K | -4.54M |
| 2019 | -9.35M | 770.42K | 6.15M |
| 2020 | -8.17M | -412.82K | 10.20M |
| 2021 | -10.21M | -329.42K | 12.10M |
| 2022 | -8.98M | -390.34K | 7.14M |
NAVB Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.23M | 2.67M | 1.04M | 3.47M | 2.79M | 1.53M | 7.16M | 5.47M | 32.93M | 9.11M |
Operating activities | ||||||||||
Net income | -15.17M | -11.73M | -10.72M | -10.94M | -16.11M | 74.94M | -14.30M | -27.56M | -35.72M | -42.69M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 95.81K | 76.95K | 70.39K | 144.51K | 150.38K | 254.58K | 501.36K | 571.41K | 500.18K | 404.18K |
Stock-based compensation expense | 301.35K | 471.26K | 230.52K | 232.05K | 0 | 394.20K | 277.53K | 2.36M | 1.63M | 2.90M |
| Deferred income tax benefit | 301.35K | 471.26K | 230.52K | 232.05K | 0 | 394.20K | 277.53K | 2.36M | 1.63M | 2.90M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 92.36K | 655.31K | 1.94M | -68.24K | 12.92M | 1.88B | 1.88B | -2.80B | 334.08K | -1.04B |
Inventories | -459.19K | 18.64K | -169.79K | 68.24K | 1.35M | 1.47M | -861.27K | 135.98K | 761.02K | -1.93M |
Accounts payable | 701.22K | 259.6K | 49.64K | 687.35K | -430.32K | -6.01M | 5.44M | 290.02K | -944.85K | 1.00M |
Cash generated by operating activities | -8.98M | -10.21M | -8.17M | -9.35M | 4.27M | 59.08M | 3.55M | -19.07M | -29.12M | -35.61M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -600K | -2.2M | 0 | 0 | -333.33K | 0 |
Investments In Property Plant And Equipment | -63.08K | -329.42K | -413.87K | -56.7K | -46.19K | -33.69K | -1.84K | -66.09K | -1.19M | -1.29M |
Acquisitions Net | 0 | 0 | 0 | 27.12K | 46.19K | 39.22M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -390.34K | -329.42K | -412.82K | 770.42K | 953.80K | -1.83M | -39.22K | -27.82K | -1.52M | -1.29M |
Financing activities | ||||||||||
Common Stock Issued | 30 | 4.34K | 4.44M | 7.08M | 3.00M | 72.41K | 13.64M | 65.97K | 87.98K | 41.30M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -17.36K | 0 | 0 | 0 | 0 | 0 | 0 | -130.53K | 0 |
Repayments of term debt | 1.98M | -491.77K | -368.55K | -359.06K | -395.57K | -59.75M | -233.60K | 24.16M | -25.00M | -5.98M |
Cash used in financing activities | 7.14M | 12.10M | 10.20M | 6.15M | -4.54M | -55.99M | -9.14M | 20.79M | 3.19M | 60.72M |
Net Change In Cash | -2.23M | 1.56M | 1.62M | -2.42M | 680.87K | 1.25M | -5.62M | 1.68M | -27.46M | 23.82M |
Cash at end of period | 1.99M | 4.23M | 2.67M | 1.04M | 3.47M | 2.79M | 1.53M | 7.16M | 5.47M | 32.93M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |